Focus: Instil Bio is a public cell therapy company focused on oncology and gene therapy, headquartered in Dallas with a pre-revenue pipeline in early-stage development.
Profile data last refreshed 14h ago · AI intelligence enriched 2mo ago
Stable — net -3 jobs in 30d
2 added, 5 removed. Backfill posture.
Instil Bio offers cutting-edge cell therapy exposure but poses substantial financial and execution risk; suitable only for candidates with high risk tolerance seeking early-stage oncology innovation.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Instil Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Instil Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: Korsana Biosciences, Inc. (CYCN) (CIK 0001755237) — 8-K
8-K
Instil Bio Inc (TIL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Instil Bio Inc (TIL) Earnings Forecast: Future EPS & Revenue Growth Estimates TradingKey
TIL|Instil Bio Inc|Price:7.410|Chg%:+0.130 - TradingKey
TIL|Instil Bio Inc|Price:7.410|Chg%:+0.130 TradingKey
Instil Bio Q1 2026 Earnings: Narrow EPS Miss, No Revenue, and Modest Stock Uptick - Analyst Drop Coverage - po-news-eg.net
Instil Bio Q1 2026 Earnings: Narrow EPS Miss, No Revenue, and Modest Stock Uptick - Analyst Drop Coverage po-news-eg.net
Instil Bio Q1 2026 Earnings: Narrow EPS Miss, No Revenue, and Modest Stock Uptick - Share Dilution Risk - dars.gov.et
Instil Bio Q1 2026 Earnings: Narrow EPS Miss, No Revenue, and Modest Stock Uptick - Share Dilution Risk dars.gov.et
8-K Filing: Cue Biopharma, Inc. (CUE) (CIK 0001645460) — 8-K
8-K
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 8 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo